Association of insurance type with unmet need for menopause care in Oregon.
Journal
Menopause (New York, N.Y.)
ISSN: 1530-0374
Titre abrégé: Menopause
Pays: United States
ID NLM: 9433353
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
1
10
2024
Statut:
aheadofprint
Résumé
To determine unmet need for menopause care in Oregon and evaluate if insurance type is associated with receipt of care. We conducted a cross-sectional survey of patients using an Oregon Listserv. Our primary outcome was use of medication for the treatment of moderate or severe symptoms of menopause. We used the Menopause Rating Scale to evaluate respondents' symptoms: 0-4 none or little symptoms; 5-8 mild symptoms; 9-16 moderate symptoms; and 17+ severe symptoms. We abstracted demographic and clinical information including age, rurality, race, ethnicity, primary language, and insurance type. We used a regression model to determine the association between public insurance and treatment for moderate to severe menopause symptoms. We examined reasons for nonuse of therapy. Our sample included 845 perimenopausal or postmenopausal individuals who were predominantly White (93.0%), aged 45-49 (32.8%) or 50-54 years (39.1%), and privately insured (81.3%). Overall, 62.4% of individuals with moderate and severe symptoms of menopause were not receiving any therapy. After adjustment for age and rurality, public insurance was associated with an average of 47% increased odds of nontreatment for moderate or severe menopause symptoms (adjusted odds ratio: 1.47, 95% CI: 0.99-2.19). The most common reasons for nontreatment in both groups were "therapy was not recommended by a provider" (43%) and worries about safety or side effects (40%). Even in well-insured persons, the majority of people with moderate and severe symptoms of menopause are not receiving treatment. People who are publicly insured are more likely to go untreated than privately insured individuals.
Identifiants
pubmed: 39352123
doi: 10.1097/GME.0000000000002437
pii: 00042192-990000000-00381
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 by The Menopause Society.
Déclaration de conflit d'intérêts
Financial disclosures/conflicts of interest: M.I.R. reports receiving grants to her institution from the NIH and Arnold Ventures during the course of the study period. S.C. receives institutional funding for PCORI, which is unrelated to this article. K.A. received past funding from Oregon ECHO Network. The other authors have nothing to disclose.
Références
Cortes YI, Coslov N, Richardson MK, Woods NF. Symptom experience during the late reproductive stage versus the menopausal transition in the Spanish-language Women Living Better survey. Menopause 2023;30:260–266. doi: 10.1097/GME.0000000000002132
doi: 10.1097/GME.0000000000002132
Baik SH, Baye F, McDonald CJ. Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses. Menopause 2024;31:363–371. doi: 10.1097/GME.0000000000002335
doi: 10.1097/GME.0000000000002335
ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 2014;123:202–216. doi: 10.1097/01.AOG.0000441353.20693.78
doi: 10.1097/01.AOG.0000441353.20693.78
Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and management options. J Clin Endocrinol Metabol 2021;106:1–15. doi: 10.1210/clinem/dgaa764
doi: 10.1210/clinem/dgaa764
Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health Across the Nation. Obstet Gynecol Clin North Am 2011;38:489–501. doi: https://doi.org/10.1016/j.ogc.2011.05.006
doi: 10.1016/j.ogc.2011.05.006
Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175:531–539. doi: 10.1001/jamainternmed.2014.8063
doi: 10.1001/jamainternmed.2014.8063
Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47. doi: 10.1186/1477-7525-3-47
doi: 10.1186/1477-7525-3-47
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–1712. doi: 10.1001/jama.291.14.1701
doi: 10.1001/jama.291.14.1701
Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353–1368. doi: 10.1001/jama.2013.278040
doi: 10.1001/jama.2013.278040
Oregon Health Authority. Reproductive Health Equity Act. 2017. Available at: https://www.oregon.gov/oha/ph/healthypeoplefamilies/reproductivesexualhealth/pages/reproductive-health-equity-act.aspx. Accessed April 24, 2020.
Oregon Health Authority. Oregon Health Insurance Survey. 2019. Available at: https://www.oregon.gov/olcc/Docs/HB3610/2019-OHIS-Early-Release-Results-Health-Insurance%20Survey.pdf. Accessed May 10, 2024.
Heinemann K, Ruebig A, Potthoff P, et al. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes 2004;2:45. doi: 10.1186/1477-7525-2-45
doi: 10.1186/1477-7525-2-45
Oregon Health Authority. Oregon Office of Rural Health Geographic Definitions. 2024. Available at: https://www.ohsu.edu/oregon-office-of-rural-health/about-rural-and-frontier-data. Accessed September 12, 2023.
The North American Menopause Society. Find a Menopause Provider. Available at: https://portal.menopause.org/NAMS/NAMS/Directory/Menopause-Practitioner.aspx. Accessed February 13, 2024.
Bonafide. State of Menopause Survey. Available at: https://hellobonafide.com/pages/state-of-menopause. Accessed April 26, 2024.
Mehta JM, Chester RC, Kling JM. The timing hypothesis: hormone therapy for treating symptomatic women during menopause and its relationship to cardiovascular disease. J Womens Health (Larchmt) 2019;28:705–711. doi: 10.1089/jwh.2018.7201
doi: 10.1089/jwh.2018.7201
Kling JM, MacLaughlin KL, Schnatz PF, et al. Menopause management knowledge in postgraduate family medicine, internal medicine, and obstetrics and gynecology residents: a cross-sectional survey. Mayo Clin Proc 2019;94:242–253. doi: 10.1016/j.mayocp.2018.08.033
doi: 10.1016/j.mayocp.2018.08.033
Vesco KK, Brooks NB, Francisco MC, et al. Resident training to optimize patient-focused menopause management: a multispecialty menopause curriculum to enhance knowledge and preparedness. Menopause 2024;31:93–100. doi: 10.1097/GME.0000000000002291
doi: 10.1097/GME.0000000000002291
Wright E, Shaltout O, Zokvic MA, Shirreff L. Delivery of menopause care during a pandemic: an evaluation of patient satisfaction with telephone visits. Menopause 2021;29:184–188. doi: 10.1097/GME.0000000000001906
doi: 10.1097/GME.0000000000001906
Kaunitz AM. Disparity in menopausal hormone therapy use between women obstetrician gynecologists and women overall: are obstetrician gynecologists underserving their patients? Menopause 2012;19:1070–1071. doi: 10.1097/gme.0b013e318261f25e
doi: 10.1097/gme.0b013e318261f25e
Wang CC, Huang DS, Carlson AM, Li Z, Al-Niaimi A, Williams M. Barriers to surgical menopause counseling in gynecologic cancers: a quantitative and qualitative study of patients and providers. Menopause 2022;29:926–931. doi: 10.1097/GME.0000000000002011
doi: 10.1097/GME.0000000000002011
Nappi RE, Kroll R, Siddiqui E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause 2021;28:875–882. doi: 10.1097/GME.0000000000001793
doi: 10.1097/GME.0000000000001793
McVicker L, Labeit AM, Coupland CAC, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol 2024;10:103–108. doi: 10.1001/jamaoncol.2023.4508
doi: 10.1001/jamaoncol.2023.4508
Kaiser Family Foundation. Medicaid Enrollees Are Sicker and More Disabled Than the Privately-Insured. 2013. Available at: https://www.kff.org/medicaid/slide/medicaid-enrollees-are-sicker-and-more-disabled-than-the-privately-insured/. Accessed May 10, 2024.